JP2008516973A - キナーゼ阻害剤 - Google Patents
キナーゼ阻害剤 Download PDFInfo
- Publication number
- JP2008516973A JP2008516973A JP2007536949A JP2007536949A JP2008516973A JP 2008516973 A JP2008516973 A JP 2008516973A JP 2007536949 A JP2007536949 A JP 2007536949A JP 2007536949 A JP2007536949 A JP 2007536949A JP 2008516973 A JP2008516973 A JP 2008516973A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hetero
- cycloalkyl
- pyrazol
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940043355 kinase inhibitor Drugs 0.000 title description 7
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 150
- 238000000034 method Methods 0.000 claims abstract description 48
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 42
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- -1 nitro, thio, hydroxy Chemical group 0.000 claims description 999
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 201000010099 disease Diseases 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 24
- 102000001253 Protein Kinase Human genes 0.000 claims description 18
- 108060006633 protein kinase Proteins 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 9
- 230000007170 pathology Effects 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000005022 packaging material Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 102000003989 Aurora kinases Human genes 0.000 claims description 3
- 108090000433 Aurora kinases Proteins 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 1265
- 125000005842 heteroatom Chemical group 0.000 claims 648
- 125000000753 cycloalkyl group Chemical group 0.000 claims 444
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 418
- 150000001602 bicycloalkyls Chemical group 0.000 claims 413
- 125000001072 heteroaryl group Chemical group 0.000 claims 389
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 354
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 307
- 229910052739 hydrogen Inorganic materials 0.000 claims 217
- 125000003118 aryl group Chemical group 0.000 claims 216
- 239000001257 hydrogen Substances 0.000 claims 216
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 214
- 125000003545 alkoxy group Chemical group 0.000 claims 213
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 181
- 125000004104 aryloxy group Chemical group 0.000 claims 178
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 177
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 177
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 177
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 176
- 125000005843 halogen group Chemical group 0.000 claims 164
- 125000003282 alkyl amino group Chemical group 0.000 claims 133
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 108
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 97
- FVLAYJRLBLHIPV-UHFFFAOYSA-N pyrimidin-5-amine Chemical compound NC1=CN=CN=C1 FVLAYJRLBLHIPV-UHFFFAOYSA-N 0.000 claims 87
- 229940124530 sulfonamide Drugs 0.000 claims 84
- 150000003456 sulfonamides Chemical class 0.000 claims 83
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims 66
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims 35
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 35
- 125000002947 alkylene group Chemical group 0.000 claims 32
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 29
- BOUIZPWBFIVJPD-UHFFFAOYSA-N 3h-1,2,4-triazin-4-amine Chemical class NN1CN=NC=C1 BOUIZPWBFIVJPD-UHFFFAOYSA-N 0.000 claims 16
- 125000004429 atom Chemical group 0.000 claims 11
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 10
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 241001024304 Mino Species 0.000 claims 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 8
- 206010012289 Dementia Diseases 0.000 claims 7
- 150000001412 amines Chemical class 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 7
- 150000001408 amides Chemical class 0.000 claims 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 6
- 208000010877 cognitive disease Diseases 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 claims 5
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 239000004202 carbamide Substances 0.000 claims 4
- WMSPXQIQBQAWLL-UHFFFAOYSA-N cyclopropanesulfonamide Chemical compound NS(=O)(=O)C1CC1 WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 claims 4
- 241000894007 species Species 0.000 claims 4
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- XRLDSWLMHUQECH-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1CCCC1 XRLDSWLMHUQECH-UHFFFAOYSA-N 0.000 claims 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 3
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 claims 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 3
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 3
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- MSSDTZLYNMFTKN-UHFFFAOYSA-N 1-Piperazinecarboxaldehyde Chemical compound O=CN1CCNCC1 MSSDTZLYNMFTKN-UHFFFAOYSA-N 0.000 claims 2
- AGRIQBHIKABLPJ-UHFFFAOYSA-N 1-Pyrrolidinecarboxaldehyde Chemical compound O=CN1CCCC1 AGRIQBHIKABLPJ-UHFFFAOYSA-N 0.000 claims 2
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 claims 2
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 claims 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- QVESPAZTKUYKFE-UHFFFAOYSA-N 7-(3-ethylsulfonylphenyl)-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC=3NN=C(C)C=3)N3C=CN=C3C=2)=C1 QVESPAZTKUYKFE-UHFFFAOYSA-N 0.000 claims 2
- MTEVLMIUCCLOJF-UHFFFAOYSA-N 7-[3-(ethylsulfonylmethyl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)CC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 MTEVLMIUCCLOJF-UHFFFAOYSA-N 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 2
- 230000006999 cognitive decline Effects 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical class 0.000 claims 2
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000005885 heterocycloalkylalkyl group Chemical class 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 2
- ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 claims 2
- 229960003966 nicotinamide Drugs 0.000 claims 2
- 235000005152 nicotinamide Nutrition 0.000 claims 2
- 239000011570 nicotinamide Substances 0.000 claims 2
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 claims 2
- ZFCHNZDUMIOWFV-UHFFFAOYSA-M pyrimidine-2-carboxylate Chemical compound [O-]C(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-M 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- HMKSATPFCVLZAD-KRWDZBQOSA-N (2s)-n-[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]oxolane-2-carboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)[C@H]3OCCC3)=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 HMKSATPFCVLZAD-KRWDZBQOSA-N 0.000 claims 1
- CMDUDMQXEVARHF-KRWDZBQOSA-N (2s)-n-[[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]pyrrolidine-2-carboxamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(CNC(=O)[C@H]3NCCC3)C=CC=2)=N1 CMDUDMQXEVARHF-KRWDZBQOSA-N 0.000 claims 1
- FYLXOUQHGOJJRI-UHFFFAOYSA-N (4-hydroxypiperidin-1-yl)-[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanone Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(C=CC=2)C(=O)N2CCC(O)CC2)=N1 FYLXOUQHGOJJRI-UHFFFAOYSA-N 0.000 claims 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims 1
- OTBFUMSMIVYLAK-UHFFFAOYSA-N 1,3-thiazole-5-sulfonamide Chemical compound NS(=O)(=O)C1=CN=CS1 OTBFUMSMIVYLAK-UHFFFAOYSA-N 0.000 claims 1
- AFCXECFLGWINNG-UHFFFAOYSA-N 1-[[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]imidazolidin-2-one Chemical compound O=C1NCCN1CC1=CC=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=CN=C3C=2)=C1 AFCXECFLGWINNG-UHFFFAOYSA-N 0.000 claims 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- ZZPZQIMGCDVBIX-UHFFFAOYSA-N 2-[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]-n-phenylacetamide Chemical compound N=1C(C2=CN(CC(=O)NC=3C=CC=CC=3)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 ZZPZQIMGCDVBIX-UHFFFAOYSA-N 0.000 claims 1
- DYADDGIMLGZAON-UHFFFAOYSA-N 2-[[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]benzonitrile Chemical compound N=1C(C2=CN(CC=3C(=CC=CC=3)C#N)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 DYADDGIMLGZAON-UHFFFAOYSA-N 0.000 claims 1
- BJQRCMRGLKTFCX-UHFFFAOYSA-N 2-[[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]benzonitrile Chemical compound N=1C(C2=CN(CC=3C(=CC=CC=3)C#N)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 BJQRCMRGLKTFCX-UHFFFAOYSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- FMMUQXDMPOTDLB-UHFFFAOYSA-N 2-methyl-7-[1-(2-methylpropyl)pyrazol-4-yl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical class C1=NN(CC(C)C)C=C1C1=CC2=NC(C)=CN2C(NC2=NNC(C)=C2)=N1 FMMUQXDMPOTDLB-UHFFFAOYSA-N 0.000 claims 1
- NWUUBYBANOEWNL-UHFFFAOYSA-N 2-methyl-7-[3-(3-methylimidazol-4-yl)phenyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C=2N(C=NC=2)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 NWUUBYBANOEWNL-UHFFFAOYSA-N 0.000 claims 1
- NMSNGWOXZGUXPU-UHFFFAOYSA-N 2-methyl-7-[3-[3-(methylamino)pyrrolidin-1-yl]sulfonylphenyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1C(NC)CCN1S(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 NMSNGWOXZGUXPU-UHFFFAOYSA-N 0.000 claims 1
- QHCODFQJYAZFBH-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-(3-piperazin-1-ylsulfonylphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)S(=O)(=O)N2CCNCC2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 QHCODFQJYAZFBH-UHFFFAOYSA-N 0.000 claims 1
- HUPVQHYRVNCWRU-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-(3-propan-2-yloxyphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CC(C)OC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 HUPVQHYRVNCWRU-UHFFFAOYSA-N 0.000 claims 1
- RWXSVGBXJSUDBT-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-(3-propoxyphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCCOC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 RWXSVGBXJSUDBT-UHFFFAOYSA-N 0.000 claims 1
- OAZQHPZMYBNBIE-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-(3-pyrrolidin-1-ylsulfonylphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)S(=O)(=O)N2CCCC2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 OAZQHPZMYBNBIE-UHFFFAOYSA-N 0.000 claims 1
- QMETZUFLUYJPNN-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[1-(1-phenylpropan-2-yl)pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1=C(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)C=NN1C(C)CC1=CC=CC=C1 QMETZUFLUYJPNN-UHFFFAOYSA-N 0.000 claims 1
- WJXWUUGUOWMEAY-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[1-(2-piperidin-1-ylethyl)pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CCN3CCCCC3)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 WJXWUUGUOWMEAY-UHFFFAOYSA-N 0.000 claims 1
- WGMYRTALXBVWPI-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[1-[[2-(trifluoromethoxy)phenyl]methyl]pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C(=CC=CC=3)OC(F)(F)F)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 WGMYRTALXBVWPI-UHFFFAOYSA-N 0.000 claims 1
- HCPAPPQGSRCYQN-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-(1,3,5-trimethylpyrazol-4-yl)phenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C2=C(N(C)N=C2C)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 HCPAPPQGSRCYQN-UHFFFAOYSA-N 0.000 claims 1
- UVPZIMVFHCTSED-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-(1,3-thiazol-2-ylsulfonyl)phenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical class N=1C(C=2C=C(C=CC=2)S(=O)(=O)C=2SC=CN=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 UVPZIMVFHCTSED-UHFFFAOYSA-N 0.000 claims 1
- GGVKDZOKPSTLDC-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-(1h-pyrrolo[2,3-b]pyridin-4-yl)phenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C=2C=3C=CNC=3N=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 GGVKDZOKPSTLDC-UHFFFAOYSA-N 0.000 claims 1
- SJXFROBNJHRXJZ-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-(3-methylpyridin-4-yl)phenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C=2C(=CN=CC=2)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 SJXFROBNJHRXJZ-UHFFFAOYSA-N 0.000 claims 1
- CFVGGCMTRZKEGF-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-(piperazin-1-ylmethyl)phenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(CN3CCNCC3)C=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 CFVGGCMTRZKEGF-UHFFFAOYSA-N 0.000 claims 1
- LJWJMBSFNXRTKZ-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-(piperidin-1-ylmethyl)phenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(CN3CCCCC3)C=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 LJWJMBSFNXRTKZ-UHFFFAOYSA-N 0.000 claims 1
- UZYXIAWQWYJODS-KRWDZBQOSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-[(3s)-pyrrolidin-3-yl]sulfonylphenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)S(=O)(=O)[C@@H]2CNCC2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 UZYXIAWQWYJODS-KRWDZBQOSA-N 0.000 claims 1
- OLTXWOKQKOFPJB-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-phenyl-2,3-dihydroimidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C)CN2C=1C=C(C=1C=CC=CC=1)N=C2NC=1C=C(C)NN=1 OLTXWOKQKOFPJB-UHFFFAOYSA-N 0.000 claims 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- JBJDYLNJACPLLX-UHFFFAOYSA-N 3-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]-n-phenylbenzenesulfonamide Chemical compound N=1C(C=2C=C(C=CC=2)S(=O)(=O)NC=2C=CC=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 JBJDYLNJACPLLX-UHFFFAOYSA-N 0.000 claims 1
- YVJWNCMKNALEFQ-UHFFFAOYSA-N 3-[3-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]propanoic acid Chemical compound N=1C(C=2C=C(CCC(O)=O)C=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 YVJWNCMKNALEFQ-UHFFFAOYSA-N 0.000 claims 1
- DVFMQGYTPGZVKT-UHFFFAOYSA-N 3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]-2-(trifluoromethyl)imidazo[1,2-c]pyrimidin-7-yl]-n-propan-2-ylbenzamide Chemical compound CC(C)NC(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(N=C3C=2)C(F)(F)F)=C1 DVFMQGYTPGZVKT-UHFFFAOYSA-N 0.000 claims 1
- LPPRBBIYICZEFR-UHFFFAOYSA-N 3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]-n-phenylbenzamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(C=CC=2)C(=O)NC=2C=CC=CC=2)=N1 LPPRBBIYICZEFR-UHFFFAOYSA-N 0.000 claims 1
- ORCOODHIVUUVOE-UHFFFAOYSA-N 3-[[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]imidazolidine-2,4-dione Chemical compound O=C1CNC(=O)N1CC1=CC=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=CN=C3C=2)=C1 ORCOODHIVUUVOE-UHFFFAOYSA-N 0.000 claims 1
- DLEFVSSWSFGQPX-UHFFFAOYSA-N 3-[[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]-n-(1,3-thiazol-2-yl)benzamide Chemical compound N=1C(C2=CN(CC=3C=C(C=CC=3)C(=O)NC=3SC=CN=3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 DLEFVSSWSFGQPX-UHFFFAOYSA-N 0.000 claims 1
- BLNSBTUIAOGZLD-UHFFFAOYSA-N 3-[[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC(CN2N=CC(=C2)C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1 BLNSBTUIAOGZLD-UHFFFAOYSA-N 0.000 claims 1
- JPOQCJAAIXGTBI-UHFFFAOYSA-N 3-[[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]benzonitrile Chemical compound N=1C(C2=CN(CC=3C=C(C=CC=3)C#N)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 JPOQCJAAIXGTBI-UHFFFAOYSA-N 0.000 claims 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 claims 1
- FVKMTLTURWXMMO-UHFFFAOYSA-N 4-fluoro-2-[[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]benzonitrile Chemical compound N=1C(C2=CN(CC=3C(=CC=C(F)C=3)C#N)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 FVKMTLTURWXMMO-UHFFFAOYSA-N 0.000 claims 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- SDAQUGZAOYECMS-UHFFFAOYSA-N 4-methyl-5-[3-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]-1,3-thiazol-2-amine Chemical compound N=1C(C=2C=C(C=CC=2)C2=C(N=C(N)S2)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 SDAQUGZAOYECMS-UHFFFAOYSA-N 0.000 claims 1
- JQTMGOLZSBTZMS-UHFFFAOYSA-N 4-methylpiperazine-1-carbaldehyde Chemical compound CN1CCN(C=O)CC1 JQTMGOLZSBTZMS-UHFFFAOYSA-N 0.000 claims 1
- JMRCUGIJPUHNTG-UHFFFAOYSA-N 5-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]-1,3-dihydrobenzimidazol-2-one Chemical compound N=1C(C=2C=C3NC(=O)NC3=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 JMRCUGIJPUHNTG-UHFFFAOYSA-N 0.000 claims 1
- MVSDXNWHSCXNAS-UHFFFAOYSA-N 7-(1-benzylpyrazol-4-yl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical class N=1C(C2=CN(CC=3C=CC=CC=3)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 MVSDXNWHSCXNAS-UHFFFAOYSA-N 0.000 claims 1
- HKECOZMPQMRCJK-UHFFFAOYSA-N 7-(1h-indol-4-yl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=3C=CNC=3C=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 HKECOZMPQMRCJK-UHFFFAOYSA-N 0.000 claims 1
- LTPSVIBVXJWVQT-UHFFFAOYSA-N 7-(2-aminophenyl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C(=CC=CC=2)N)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 LTPSVIBVXJWVQT-UHFFFAOYSA-N 0.000 claims 1
- UGCNIQVBHFPXNJ-UHFFFAOYSA-N 7-(3-ethylsulfanylphenyl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCSC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 UGCNIQVBHFPXNJ-UHFFFAOYSA-N 0.000 claims 1
- JOTRISSZVLESNJ-UHFFFAOYSA-N 7-(3-ethylsulfinylphenyl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 JOTRISSZVLESNJ-UHFFFAOYSA-N 0.000 claims 1
- GHHGEXOQPOBCPJ-UHFFFAOYSA-N 7-(3-ethylsulfonylphenyl)-2-(imidazol-1-ylmethyl)-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(CN4C=NC=C4)N=C3C=2)=C1 GHHGEXOQPOBCPJ-UHFFFAOYSA-N 0.000 claims 1
- OFRHKIQDPFRXSH-UHFFFAOYSA-N 7-(3-ethylsulfonylphenyl)-2-[(4-methylpiperazin-1-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(CN4CCN(C)CC4)N=C3C=2)=C1 OFRHKIQDPFRXSH-UHFFFAOYSA-N 0.000 claims 1
- YVLCDISVYKDXJC-UHFFFAOYSA-N 7-(3-ethylsulfonylphenyl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 YVLCDISVYKDXJC-UHFFFAOYSA-N 0.000 claims 1
- JVNZYHOPDGUBTK-UHFFFAOYSA-N 7-(3-ethylsulfonylphenyl)-n-(5-methyl-1h-pyrazol-3-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3N=CN=C3C=2)=C1 JVNZYHOPDGUBTK-UHFFFAOYSA-N 0.000 claims 1
- OMHDEXPHTJYNEI-UHFFFAOYSA-N 7-(4-methoxy-3-morpholin-4-ylsulfonylphenyl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound COC1=CC=C(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)C=C1S(=O)(=O)N1CCOCC1 OMHDEXPHTJYNEI-UHFFFAOYSA-N 0.000 claims 1
- CFHDCDMYZFTSAV-UHFFFAOYSA-N 7-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1CN(C)CCN1C1=CC2=NC=CN2C(NC2=NNC(C)=C2)=N1 CFHDCDMYZFTSAV-UHFFFAOYSA-N 0.000 claims 1
- ROWMGPCTWSWMLA-UHFFFAOYSA-N 7-[(2-methoxyphenyl)methyl]-5-N-(5-methyl-1H-pyrazol-3-yl)-3H-imidazo[1,2-c]pyrimidine-5,7-diamine Chemical compound COC1=C(CC2(C=C3N(C(=N2)NC2=NNC(=C2)C)CC=N3)N)C=CC=C1 ROWMGPCTWSWMLA-UHFFFAOYSA-N 0.000 claims 1
- DFBVARVABSDNCV-UHFFFAOYSA-N 7-[1-(2,1,3-benzoxadiazol-5-ylmethyl)pyrazol-4-yl]-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methylimidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC3=CC4=NON=C4C=C3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 DFBVARVABSDNCV-UHFFFAOYSA-N 0.000 claims 1
- XSAAHTFHNKFPNW-UHFFFAOYSA-N 7-[1-[(2,5-dichlorophenyl)methyl]pyrazol-4-yl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C(=CC=C(Cl)C=3)Cl)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 XSAAHTFHNKFPNW-UHFFFAOYSA-N 0.000 claims 1
- MYHARYFKAQQZMM-UHFFFAOYSA-N 7-[1-[(3-aminophenyl)methyl]pyrazol-4-yl]-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methylimidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C=C(N)C=CC=3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 MYHARYFKAQQZMM-UHFFFAOYSA-N 0.000 claims 1
- XBQSCCQLFHQSJD-UHFFFAOYSA-N 7-[3-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C2=C(ON=C2C)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 XBQSCCQLFHQSJD-UHFFFAOYSA-N 0.000 claims 1
- AHPLJNPKWIXLLC-UHFFFAOYSA-N 7-[3-(3,5-dimethyl-1h-pyrazol-4-yl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C2=C(NN=C2C)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 AHPLJNPKWIXLLC-UHFFFAOYSA-N 0.000 claims 1
- QTAVJFWUXAOGCR-UHFFFAOYSA-N 7-[3-(3-aminopropylsulfonyl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)S(=O)(=O)CCCN)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 QTAVJFWUXAOGCR-UHFFFAOYSA-N 0.000 claims 1
- RYWMDXDWVSSEPC-UHFFFAOYSA-N 7-[3-(3-cyclopropyl-5-methyl-1h-pyrazol-4-yl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C2=C(NN=C2C)C2CC2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 RYWMDXDWVSSEPC-UHFFFAOYSA-N 0.000 claims 1
- OCLLIGFYGZHCQI-UHFFFAOYSA-N 7-[3-(4-methylpiperazin-1-yl)sulfonylphenyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=CN=C3C=2)=C1 OCLLIGFYGZHCQI-UHFFFAOYSA-N 0.000 claims 1
- ZOYITUNLCDHCJW-UHFFFAOYSA-N 7-[3-(5-amino-2-methylthiophen-3-yl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C2=C(SC(N)=C2)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 ZOYITUNLCDHCJW-UHFFFAOYSA-N 0.000 claims 1
- MDDJVEBBFLQMIG-UHFFFAOYSA-N 7-[3-(aminomethyl)phenyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(CN)C=CC=2)=N1 MDDJVEBBFLQMIG-UHFFFAOYSA-N 0.000 claims 1
- TXFDEBRJWSOAFQ-UHFFFAOYSA-N 7-[3-(diethylamino)pyrrolidin-1-yl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1C(N(CC)CC)CCN1C1=CC2=NC(C)=CN2C(NC2=NNC(C)=C2)=N1 TXFDEBRJWSOAFQ-UHFFFAOYSA-N 0.000 claims 1
- QQDAPZQSEASFIW-UHFFFAOYSA-N 7-[3-(methylaminomethyl)phenyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CNCC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=CN=C3C=2)=C1 QQDAPZQSEASFIW-UHFFFAOYSA-N 0.000 claims 1
- AATNTJQPQQQBGQ-UHFFFAOYSA-N 7-[3-[(cyclopropylmethylamino)methyl]phenyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical class N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(CNCC3CC3)C=CC=2)=N1 AATNTJQPQQQBGQ-UHFFFAOYSA-N 0.000 claims 1
- AETIMTKIXAUWJV-UHFFFAOYSA-N 7-[3-[(dimethylamino)methyl]-1-ethylsulfonylindol-6-yl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1=C2N(S(=O)(=O)CC)C=C(CN(C)C)C2=CC=C1C(N=1)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 AETIMTKIXAUWJV-UHFFFAOYSA-N 0.000 claims 1
- ZBAYWIKUKPUVIC-UHFFFAOYSA-N 7-[3-[2-(dimethylamino)ethoxy]phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CN(C)CCOC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 ZBAYWIKUKPUVIC-UHFFFAOYSA-N 0.000 claims 1
- IHVBPMAJQOWPBQ-UHFFFAOYSA-N 7-[4-methoxy-3-(oxan-4-ylsulfonyl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound COC1=CC=C(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)C=C1S(=O)(=O)C1CCOCC1 IHVBPMAJQOWPBQ-UHFFFAOYSA-N 0.000 claims 1
- RRVZEOLKRYJCHF-UHFFFAOYSA-N 7-n,2-dimethyl-5-n-(5-methyl-1h-pyrazol-3-yl)-7-n-(1-methylpyrrolidin-3-yl)imidazo[1,2-c]pyrimidine-5,7-diamine Chemical compound C=1C2=NC(C)=CN2C(NC2=NNC(C)=C2)=NC=1N(C)C1CCN(C)C1 RRVZEOLKRYJCHF-UHFFFAOYSA-N 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 102000004228 Aurora kinase B Human genes 0.000 claims 1
- 108090000749 Aurora kinase B Proteins 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- ZJBCLKIVGXYVOI-UHFFFAOYSA-N CC1=CC(C(N)(N(CC=N2)C2=C2)N=C2N)=NN1 Chemical class CC1=CC(C(N)(N(CC=N2)C2=C2)N=C2N)=NN1 ZJBCLKIVGXYVOI-UHFFFAOYSA-N 0.000 claims 1
- GHMWFUVGWJRZAJ-UHFFFAOYSA-N CC1=CN2C(=N1)C=C(N=C2NC3=NNC(=C3)C4CC4)C5=CN(N=C5)CC6=CC(=CC=C6)C(=O)O Chemical compound CC1=CN2C(=N1)C=C(N=C2NC3=NNC(=C3)C4CC4)C5=CN(N=C5)CC6=CC(=CC=C6)C(=O)O GHMWFUVGWJRZAJ-UHFFFAOYSA-N 0.000 claims 1
- MKECCGGGUOKIOE-UHFFFAOYSA-N CCNC(=O)C(CC(=O)N)C1=CC=CC(=C1)C2=CC3=NC(=CN3C(=N2)NC4=NNC(=C4)C5CC5)C Chemical compound CCNC(=O)C(CC(=O)N)C1=CC=CC(=C1)C2=CC3=NC(=CN3C(=N2)NC4=NNC(=C4)C5CC5)C MKECCGGGUOKIOE-UHFFFAOYSA-N 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- GLGIYDRFAKEOES-UHFFFAOYSA-N [3-[(7-phenylimidazo[1,2-c]pyrimidin-5-yl)amino]-1h-pyrazol-5-yl]methanol Chemical compound N1C(CO)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=CC=CC=2)=N1 GLGIYDRFAKEOES-UHFFFAOYSA-N 0.000 claims 1
- AHGWVMGORPUDIT-UHFFFAOYSA-N [5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-7-(3-ethylsulfonylphenyl)imidazo[1,2-c]pyrimidin-2-yl]methanol Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(CO)N=C3C=2)=C1 AHGWVMGORPUDIT-UHFFFAOYSA-N 0.000 claims 1
- DURKWYKYYAVXDM-UHFFFAOYSA-N [7-(3-ethylsulfonylphenyl)-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-2-yl]methanol Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(CO)N=C3C=2)=C1 DURKWYKYYAVXDM-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000005157 alkyl carboxy group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000005336 allyloxy group Chemical group 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010068168 androgenetic alopecia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- JXPIMUCXJYUKIK-UHFFFAOYSA-N but-2-ynyl n-[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]carbamate Chemical compound C1=CC(NC(=O)OCC#CC)=CC=C1SC1=CC2=NC=CN2C(NC2=NNC(=C2)C2CC2)=N1 JXPIMUCXJYUKIK-UHFFFAOYSA-N 0.000 claims 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 229940047889 isobutyramide Drugs 0.000 claims 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- YDOQGSFPEWLAKN-UHFFFAOYSA-N methyl 3-[3-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]propanoate Chemical compound COC(=O)CCC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 YDOQGSFPEWLAKN-UHFFFAOYSA-N 0.000 claims 1
- RVUXRYWMGJASCA-UHFFFAOYSA-N methyl 4-[[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1N=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 RVUXRYWMGJASCA-UHFFFAOYSA-N 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 1
- ONRNZCSJNWMBKI-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-(ethoxymethyl)-7-(3-ethylsulfonylphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)S(=O)(=O)CC)=CC2=NC(COCC)=CN2C=1NC(=NN1)C=C1C1CC1 ONRNZCSJNWMBKI-UHFFFAOYSA-N 0.000 claims 1
- WFYAEANAIZADDY-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-(2-morpholin-4-ylethyl)pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CCN3CCOCC3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 WFYAEANAIZADDY-UHFFFAOYSA-N 0.000 claims 1
- AZIJEPBVMATVKF-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-(3-methylbutyl)pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1=NN(CCC(C)C)C=C1C1=CC2=NC(C)=CN2C(NC2=NNC(=C2)C2CC2)=N1 AZIJEPBVMATVKF-UHFFFAOYSA-N 0.000 claims 1
- UYANHYRKBSXTHC-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-(pyridin-2-ylmethyl)pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3N=CC=CC=3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 UYANHYRKBSXTHC-UHFFFAOYSA-N 0.000 claims 1
- DLQXOLXQCSNNCE-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-(quinolin-8-ylmethyl)pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C4=NC=CC=C4C=CC=3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 DLQXOLXQCSNNCE-UHFFFAOYSA-N 0.000 claims 1
- VTMWPYSEQYVEKS-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-[(3-nitrophenyl)methyl]pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C=C(C=CC=3)[N+]([O-])=O)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 VTMWPYSEQYVEKS-UHFFFAOYSA-N 0.000 claims 1
- LKRDPFBOIUVFPF-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-[(3-pyrrol-1-ylphenyl)methyl]pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C=C(C=CC=3)N3C=CC=C3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 LKRDPFBOIUVFPF-UHFFFAOYSA-N 0.000 claims 1
- JTFDLBWMTYKDHH-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-[(4-pyrazol-1-ylphenyl)methyl]pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C=CC(=CC=3)N3N=CC=C3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 JTFDLBWMTYKDHH-UHFFFAOYSA-N 0.000 claims 1
- MELKKSOYORGVIB-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-(2,3-dihydro-1-benzofuran-5-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1CC1C1=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C3CCOC3=CC=2)=NN1 MELKKSOYORGVIB-UHFFFAOYSA-N 0.000 claims 1
- QCLFRXLRKRKCCI-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-(2,3-dihydroindol-1-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1CC1C1=CC(NC=2N3C=CN=C3C=C(N=2)N2C3=CC=CC=C3CC2)=NN1 QCLFRXLRKRKCCI-UHFFFAOYSA-N 0.000 claims 1
- NGMPKDXNIYGWOQ-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-(3,4-dihydro-1h-isoquinolin-2-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1CC1C1=CC(NC=2N3C=CN=C3C=C(N=2)N2CC3=CC=CC=C3CC2)=NN1 NGMPKDXNIYGWOQ-UHFFFAOYSA-N 0.000 claims 1
- BOGQGBDABAFWMP-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-(3-ethylsulfonylphenyl)-2-[(4-methylpiperazin-1-yl)methyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(CN4CCN(C)CC4)N=C3C=2)=C1 BOGQGBDABAFWMP-UHFFFAOYSA-N 0.000 claims 1
- OHAIZFBNNWKUIM-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-(3-ethylsulfonylphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC=3NN=C(C=3)C3CC3)N3C=CN=C3C=2)=C1 OHAIZFBNNWKUIM-UHFFFAOYSA-N 0.000 claims 1
- YZWBADIZXZDZPW-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-[1-[(2,3-dimethoxyphenyl)methyl]pyrazol-4-yl]-2-methylimidazo[1,2-c]pyrimidin-5-amine Chemical compound COC1=CC=CC(CN2N=CC(=C2)C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1OC YZWBADIZXZDZPW-UHFFFAOYSA-N 0.000 claims 1
- RLFRRBJZIHHNGJ-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-[1-[(3,5-dimethoxyphenyl)methyl]pyrazol-4-yl]-2-methylimidazo[1,2-c]pyrimidin-5-amine Chemical compound COC1=CC(OC)=CC(CN2N=CC(=C2)C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1 RLFRRBJZIHHNGJ-UHFFFAOYSA-N 0.000 claims 1
- DWFQRZNROTUJJE-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-[1-[(3-methoxyphenyl)methyl]pyrazol-4-yl]-2-methylimidazo[1,2-c]pyrimidin-5-amine Chemical compound COC1=CC=CC(CN2N=CC(=C2)C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1 DWFQRZNROTUJJE-UHFFFAOYSA-N 0.000 claims 1
- LGERUKVWJHEAEY-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-[1-[(4-methoxyphenyl)methyl]pyrazol-4-yl]-2-methylimidazo[1,2-c]pyrimidin-5-amine Chemical compound C1=CC(OC)=CC=C1CN1N=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1 LGERUKVWJHEAEY-UHFFFAOYSA-N 0.000 claims 1
- HLOFFXFIJVZECX-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-2,7-diphenylimidazo[1,2-c]pyrimidin-5-amine Chemical compound N1C(C)=CC(NC=2N3C=C(N=C3C=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 HLOFFXFIJVZECX-UHFFFAOYSA-N 0.000 claims 1
- VPQBXMMVYAODPG-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-6-phenylimidazo[1,2-a]pyrazin-8-amine Chemical compound N1C(C)=CC(NC=2C3=NC=CN3C=C(N=2)C=2C=CC=CC=2)=N1 VPQBXMMVYAODPG-UHFFFAOYSA-N 0.000 claims 1
- ZKAAGHMZAJSBGN-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-6-piperidin-1-ylimidazo[1,2-a]pyrazin-8-amine Chemical compound N1C(C)=CC(NC=2C3=NC=CN3C=C(N=2)N2CCCCC2)=N1 ZKAAGHMZAJSBGN-UHFFFAOYSA-N 0.000 claims 1
- WFWLQEJPFGTKQP-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-7-(1,2,3,4-tetrahydroisoquinolin-7-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical class N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C3CNCCC3=CC=2)=N1 WFWLQEJPFGTKQP-UHFFFAOYSA-N 0.000 claims 1
- LTVLIBKBGHODBB-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-7-(2-methylsulfonyl-3,4-dihydro-1h-isoquinolin-7-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C3CN(CCC3=CC=2)S(C)(=O)=O)=N1 LTVLIBKBGHODBB-UHFFFAOYSA-N 0.000 claims 1
- GXIPJBWNVDKOMB-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-7-(3-methylsulfonylphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(C=CC=2)S(C)(=O)=O)=N1 GXIPJBWNVDKOMB-UHFFFAOYSA-N 0.000 claims 1
- GZYUZBROUKLZAA-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-7-piperidin-1-ylimidazo[1,2-c]pyrimidin-5-amine Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)N2CCCCC2)=N1 GZYUZBROUKLZAA-UHFFFAOYSA-N 0.000 claims 1
- JNLYNHDNQCEBGQ-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethoxy]-5-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]cyclopropanesulfonamide Chemical compound CN(C)CCOC1=CC=C(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)C=C1NS(=O)(=O)C1CC1 JNLYNHDNQCEBGQ-UHFFFAOYSA-N 0.000 claims 1
- WKVNWHBJXLKDMT-UHFFFAOYSA-N n-[2-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC2=NC(C)=CN2C(NC2=NNC(C)=C2)=N1 WKVNWHBJXLKDMT-UHFFFAOYSA-N 0.000 claims 1
- NMEKGDXDEWKVJY-UHFFFAOYSA-N n-[2-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound N=1C(C=2C(=CC=CC=2)NS(C)(=O)=O)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 NMEKGDXDEWKVJY-UHFFFAOYSA-N 0.000 claims 1
- RHBIBVBVJHEJEW-UHFFFAOYSA-N n-[3-[2-(hydroxymethyl)-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound N1C(C)=CC(NC=2N3C=C(CO)N=C3C=C(N=2)C=2C=C(NS(C)(=O)=O)C=CC=2)=N1 RHBIBVBVJHEJEW-UHFFFAOYSA-N 0.000 claims 1
- PPLSEHYNYVUXJH-UHFFFAOYSA-N n-[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-(hydroxymethyl)imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2N=C(NC=3NN=C(C=3)C3CC3)N3C=C(CO)N=C3C=2)=C1 PPLSEHYNYVUXJH-UHFFFAOYSA-N 0.000 claims 1
- BTCWEXSFTBTCHL-UHFFFAOYSA-N n-[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-[(4-methylpiperazin-1-yl)methyl]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound C1CN(C)CCN1CC1=CN(C(NC2=NNC(=C2)C2CC2)=NC(=C2)C=3C=C(NS(C)(=O)=O)C=CC=3)C2=N1 BTCWEXSFTBTCHL-UHFFFAOYSA-N 0.000 claims 1
- YQTJPLAZZVSTFZ-UHFFFAOYSA-N n-[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(SC=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1 YQTJPLAZZVSTFZ-UHFFFAOYSA-N 0.000 claims 1
- MILFCSCDTPTHNF-UHFFFAOYSA-N n-[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N=C(NC=3NN=C(C=3)C3CC3)N3C=CN=C3C=2)=C1 MILFCSCDTPTHNF-UHFFFAOYSA-N 0.000 claims 1
- CNNMOOWTPIVKQN-UHFFFAOYSA-N n-[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2N=C(NC=3NN=C(C=3)C3CC3)N3C=CN=C3C=2)=C1 CNNMOOWTPIVKQN-UHFFFAOYSA-N 0.000 claims 1
- MKUDBHGZQHOIKV-UHFFFAOYSA-N n-[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound N1N=C(C)C=C1NC1=NC(C=2C=C(NS(C)(=O)=O)C=CC=2)=CC2=NC=CN12 MKUDBHGZQHOIKV-UHFFFAOYSA-N 0.000 claims 1
- JTZJXBCFJBHHAX-UHFFFAOYSA-N n-[3-[[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]phenyl]-2-methoxyacetamide Chemical compound COCC(=O)NC1=CC=CC(CN2N=CC(=C2)C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1 JTZJXBCFJBHHAX-UHFFFAOYSA-N 0.000 claims 1
- QVSDSLSMBVIGBP-UHFFFAOYSA-N n-[4-[2-(hydroxymethyl)-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2N3C=C(CO)N=C3C=C(SC=3C=CC(NC(=O)C4CC4)=CC=3)N=2)=N1 QVSDSLSMBVIGBP-UHFFFAOYSA-N 0.000 claims 1
- MQLLYGMTCOEXND-UHFFFAOYSA-N n-[4-[2-(methylaminomethyl)-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C3CC3)=CC=2)=CC2=NC(CNC)=CN2C=1NC=1C=C(C)NN=1 MQLLYGMTCOEXND-UHFFFAOYSA-N 0.000 claims 1
- POGGWKADGDCMQM-UHFFFAOYSA-N n-[4-[2-[(2-hydroxyethylamino)methyl]-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2N3C=C(CNCCO)N=C3C=C(SC=3C=CC(NC(=O)C4CC4)=CC=3)N=2)=N1 POGGWKADGDCMQM-UHFFFAOYSA-N 0.000 claims 1
- OKGVUECBUKZCEW-UHFFFAOYSA-N n-[4-[2-[(dimethylamino)methyl]-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C3CC3)=CC=2)=CC2=NC(CN(C)C)=CN2C=1NC=1C=C(C)NN=1 OKGVUECBUKZCEW-UHFFFAOYSA-N 0.000 claims 1
- PINFCAYNXOYQLC-UHFFFAOYSA-N n-[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]-1,2-oxazole-5-carboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C=3ON=CC=3)=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 PINFCAYNXOYQLC-UHFFFAOYSA-N 0.000 claims 1
- KNXCBOOEGDKLLA-UHFFFAOYSA-N n-[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=CC2=NC(C)=CN2C(NC2=NNC(C)=C2)=N1 KNXCBOOEGDKLLA-UHFFFAOYSA-N 0.000 claims 1
- BULOJFGDSWJZLE-UHFFFAOYSA-N n-[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C3CC3)=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 BULOJFGDSWJZLE-UHFFFAOYSA-N 0.000 claims 1
- RDGCAFVJLOGBOC-UHFFFAOYSA-N n-[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]furan-2-carboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C=3OC=CC=3)=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 RDGCAFVJLOGBOC-UHFFFAOYSA-N 0.000 claims 1
- BGNGXBCGISADRM-UHFFFAOYSA-N n-[4-[2-methyl-8-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrazin-6-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1=C(NC2=NNC(C)=C2)C2=NC(C)=CN2C=C1SC(C=C1)=CC=C1NC(=O)C1CC1 BGNGXBCGISADRM-UHFFFAOYSA-N 0.000 claims 1
- NNAKLZSAAGXJII-UHFFFAOYSA-N n-[4-[3-methyl-8-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrazin-6-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2C3=NC=C(C)N3C=C(SC=3C=CC(NC(=O)C4CC4)=CC=3)N=2)=N1 NNAKLZSAAGXJII-UHFFFAOYSA-N 0.000 claims 1
- YVKFZSRJUICEEK-UHFFFAOYSA-N n-[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-(methoxymethyl)imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]-2-methoxyacetamide Chemical compound C1=CC(NC(=O)COC)=CC=C1SC1=CC2=NC(COC)=CN2C(NC2=NNC(=C2)C2CC2)=N1 YVKFZSRJUICEEK-UHFFFAOYSA-N 0.000 claims 1
- NMGQHZSDJYLJRB-UHFFFAOYSA-N n-[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-[(dimethylamino)methyl]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]acetamide Chemical compound N=1C(SC=2C=CC(NC(C)=O)=CC=2)=CC2=NC(CN(C)C)=CN2C=1NC(=NN1)C=C1C1CC1 NMGQHZSDJYLJRB-UHFFFAOYSA-N 0.000 claims 1
- XNZQABBSBCFIOW-UHFFFAOYSA-N n-[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]-1,5-dimethylpyrazole-3-carboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C3=NN(C)C(C)=C3)=CC=2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 XNZQABBSBCFIOW-UHFFFAOYSA-N 0.000 claims 1
- XWFCAOGLMUJWRL-UHFFFAOYSA-N n-[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]-2,5-dimethylpyrazole-3-carboxamide Chemical compound CN1N=C(C)C=C1C(=O)NC(C=C1)=CC=C1SC1=CC2=NC(C)=CN2C(NC2=NNC(=C2)C2CC2)=N1 XWFCAOGLMUJWRL-UHFFFAOYSA-N 0.000 claims 1
- WDEFALGXDKDULP-UHFFFAOYSA-N n-[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]-5-methylfuran-2-carboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C=3OC(C)=CC=3)=CC=2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 WDEFALGXDKDULP-UHFFFAOYSA-N 0.000 claims 1
- CYIOGEPASGEMLP-UHFFFAOYSA-N n-[4-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrimidin-7-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC2=NC=CN2C(NC2=NNC(C)=C2)=C1 CYIOGEPASGEMLP-UHFFFAOYSA-N 0.000 claims 1
- RMVNHLFCNRUPDK-UHFFFAOYSA-N n-[4-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrimidin-7-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3N=C(SC=3C=CC(NC(=O)C4CC4)=CC=3)C=2)=N1 RMVNHLFCNRUPDK-UHFFFAOYSA-N 0.000 claims 1
- ZIDATLVNPVBACP-UHFFFAOYSA-N n-[4-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]oxolane-2-carboxamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(SC=3C=CC(NC(=O)C4OCCC4)=CC=3)N=2)=N1 ZIDATLVNPVBACP-UHFFFAOYSA-N 0.000 claims 1
- QZXDISDNIDKGEH-UHFFFAOYSA-N n-[4-[6-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrazin-8-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC(NC2=NNC(C)=C2)=CN2C1=NC=C2 QZXDISDNIDKGEH-UHFFFAOYSA-N 0.000 claims 1
- OBIROORVJGREFD-UHFFFAOYSA-N n-[4-[6-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrazin-8-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2N=C(SC=3C=CC(NC(=O)C4CC4)=CC=3)C3=NC=CN3C=2)=N1 OBIROORVJGREFD-UHFFFAOYSA-N 0.000 claims 1
- JCNSRZSTPRJMFY-UHFFFAOYSA-N n-[4-[8-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrazin-6-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC(N=C1NC2=NNC(C)=C2)=CN2C1=NC=C2 JCNSRZSTPRJMFY-UHFFFAOYSA-N 0.000 claims 1
- MAPCSAGZTZJTIK-UHFFFAOYSA-N n-[4-[8-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrazin-6-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2C3=NC=CN3C=C(SC=3C=CC(NC(=O)C4CC4)=CC=3)N=2)=N1 MAPCSAGZTZJTIK-UHFFFAOYSA-N 0.000 claims 1
- BXYGAGCLZPUAIB-UHFFFAOYSA-N n-[5-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]-2-(2-morpholin-4-ylethoxy)phenyl]cyclopropanesulfonamide Chemical compound N=1C(C=2C=C(NS(=O)(=O)C3CC3)C(OCCN3CCOCC3)=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 BXYGAGCLZPUAIB-UHFFFAOYSA-N 0.000 claims 1
- FKZDBAMCOCDDGR-UHFFFAOYSA-N n-[[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=CN=C3C=2)=C1 FKZDBAMCOCDDGR-UHFFFAOYSA-N 0.000 claims 1
- WUVZWWRIURNSOM-UHFFFAOYSA-N n-[[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]cyclopentanecarboxamide Chemical compound C1CCCC1C(=O)NCC(C=1)=CC=CC=1C(N=1)=CC2=NC=CN2C=1NC(=NN1)C=C1C1CC1 WUVZWWRIURNSOM-UHFFFAOYSA-N 0.000 claims 1
- OXFVZRQAFFEJGX-UHFFFAOYSA-N n-[[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NCC(C=1)=CC=CC=1C(N=1)=CC2=NC=CN2C=1NC(=NN1)C=C1C1CC1 OXFVZRQAFFEJGX-UHFFFAOYSA-N 0.000 claims 1
- STGDPPYTPHYUKB-UHFFFAOYSA-N n-[[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]methanesulfonamide Chemical compound CS(=O)(=O)NCC1=CC=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=CN=C3C=2)=C1 STGDPPYTPHYUKB-UHFFFAOYSA-N 0.000 claims 1
- SAMFUIMKMTZLDQ-UHFFFAOYSA-N n-[[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]azetidine-3-carboxamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(CNC(=O)C3CNC3)C=CC=2)=N1 SAMFUIMKMTZLDQ-UHFFFAOYSA-N 0.000 claims 1
- MNGHTLDQGOLCSD-UHFFFAOYSA-N n-[[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(CNC(=O)C3CC3)C=CC=2)=N1 MNGHTLDQGOLCSD-UHFFFAOYSA-N 0.000 claims 1
- JZCYCFNAOXZGOS-UHFFFAOYSA-N n-[[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]cyclopropanesulfonamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(CNS(=O)(=O)C3CC3)C=CC=2)=N1 JZCYCFNAOXZGOS-UHFFFAOYSA-N 0.000 claims 1
- NMZCCRDYLSGLFD-UHFFFAOYSA-N n-[[4-fluoro-3-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]cyclopropanecarboxamide Chemical compound N=1C(C=2C(=CC=C(CNC(=O)C3CC3)C=2)F)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 NMZCCRDYLSGLFD-UHFFFAOYSA-N 0.000 claims 1
- DMVQCFZDIMWKOW-UHFFFAOYSA-N n-[[4-fluoro-3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C(=CC=C(CNC(=O)C3CC3)C=2)F)=N1 DMVQCFZDIMWKOW-UHFFFAOYSA-N 0.000 claims 1
- FVBNFGJCTMZTJD-UHFFFAOYSA-N n-cyclopropyl-5-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]thiophene-2-carboxamide Chemical compound N=1C(C=2SC(=CC=2)C(=O)NC2CC2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 FVBNFGJCTMZTJD-UHFFFAOYSA-N 0.000 claims 1
- SZRPNHVPLCLXOD-UHFFFAOYSA-N n-ethyl-4-[[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1CN1N=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 SZRPNHVPLCLXOD-UHFFFAOYSA-N 0.000 claims 1
- BQSMTUBJVMUNBP-UHFFFAOYSA-N n-ethyl-n-[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]-2-propan-2-ylimidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound CCN(S(C)(=O)=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(N=C3C=2)C(C)C)=C1 BQSMTUBJVMUNBP-UHFFFAOYSA-N 0.000 claims 1
- YVXCZYSZTJVOHE-UHFFFAOYSA-N n-methyl-n-[[3-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]ethanesulfonamide Chemical compound CCS(=O)(=O)N(C)CC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 YVXCZYSZTJVOHE-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 1
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 1
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims 1
- XIMBESZRBTVIOD-UHFFFAOYSA-N piperidine-2-carboxamide Chemical compound NC(=O)C1CCCCN1 XIMBESZRBTVIOD-UHFFFAOYSA-N 0.000 claims 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- DROIHSMGGKKIJT-UHFFFAOYSA-N propane-1-sulfonamide Chemical compound CCCS(N)(=O)=O DROIHSMGGKKIJT-UHFFFAOYSA-N 0.000 claims 1
- SJMCLWCCNYAWRQ-UHFFFAOYSA-N propane-2-sulfonamide Chemical compound CC(C)S(N)(=O)=O SJMCLWCCNYAWRQ-UHFFFAOYSA-N 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 claims 1
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 claims 1
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 claims 1
- IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical compound NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 102100032306 Aurora kinase B Human genes 0.000 description 4
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000009822 protein phosphorylation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 101100261976 Drosophila melanogaster trk gene Proteins 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 101150036586 FES gene Proteins 0.000 description 1
- 101150017750 FGFRL1 gene Proteins 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- 102100026149 Fibroblast growth factor receptor-like 1 Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 1
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000006391 Ion Pumps Human genes 0.000 description 1
- 108010083687 Ion Pumps Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 101150054473 PTK2 gene Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 101100517381 Rattus norvegicus Ntrk1 gene Proteins 0.000 description 1
- 101100091511 Rhizobium radiobacter ros gene Proteins 0.000 description 1
- 101100537955 Schizosaccharomyces pombe (strain 972 / ATCC 24843) trk1 gene Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61930204P | 2004-10-15 | 2004-10-15 | |
| US67969005P | 2005-05-11 | 2005-05-11 | |
| PCT/US2005/037059 WO2006044687A2 (en) | 2004-10-15 | 2005-10-14 | Kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011284364A Division JP5524171B2 (ja) | 2004-10-15 | 2011-12-26 | キナーゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008516973A true JP2008516973A (ja) | 2008-05-22 |
| JP2008516973A5 JP2008516973A5 (https=) | 2008-12-04 |
Family
ID=35677430
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536949A Withdrawn JP2008516973A (ja) | 2004-10-15 | 2005-10-14 | キナーゼ阻害剤 |
| JP2011284364A Expired - Fee Related JP5524171B2 (ja) | 2004-10-15 | 2011-12-26 | キナーゼ阻害剤 |
| JP2013006060A Ceased JP2013121966A (ja) | 2004-10-15 | 2013-01-17 | キナーゼ阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011284364A Expired - Fee Related JP5524171B2 (ja) | 2004-10-15 | 2011-12-26 | キナーゼ阻害剤 |
| JP2013006060A Ceased JP2013121966A (ja) | 2004-10-15 | 2013-01-17 | キナーゼ阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7713973B2 (https=) |
| EP (1) | EP1812439B2 (https=) |
| JP (3) | JP2008516973A (https=) |
| AT (1) | ATE479687T1 (https=) |
| DE (1) | DE602005023333D1 (https=) |
| WO (1) | WO2006044687A2 (https=) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008545660A (ja) * | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| JP2012505234A (ja) * | 2008-10-08 | 2012-03-01 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
| JP2012517965A (ja) * | 2009-02-13 | 2012-08-09 | バイエル ファーマ アクチエンゲゼルシャフト | Ａｋｔインヒビターとしての融合されたピリミジン |
| JP2013523884A (ja) * | 2010-04-14 | 2013-06-17 | アレイ バイオファーマ、インコーポレイテッド | ＪＡＫキナーゼの阻害剤としての５，７置換イミダゾ［１，２−ｃ］ピリミジン |
| JP2015518010A (ja) * | 2012-05-31 | 2015-06-25 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ | ピロロ［２，１−ｆ］［１，２，４］トリアジン系化合物、その製造方法および用途 |
| JP2017511365A (ja) * | 2014-04-17 | 2017-04-20 | アッヴィ・インコーポレイテッド | 複素環キナーゼ阻害薬 |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003284237A1 (en) * | 2002-10-16 | 2004-05-04 | Transport Systems, Inc. | Monorail sortation system |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| ATE479687T1 (de) * | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| JP2008520713A (ja) | 2004-11-17 | 2008-06-19 | ミイカナ セラピューティクス インコーポレイテッド | キナーゼ阻害剤 |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US7232901B2 (en) * | 2005-07-01 | 2007-06-19 | Bristol-Myers Squibb Company | Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates |
| US7442700B2 (en) * | 2005-07-01 | 2008-10-28 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| CA2615374A1 (en) * | 2005-07-18 | 2007-01-25 | Ernest Kun Kun | Treatment of cancer |
| CA2622352C (en) * | 2005-09-30 | 2014-05-27 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| JP5182088B2 (ja) * | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
| US7893058B2 (en) * | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| HRP20140688T1 (hr) * | 2006-07-07 | 2014-10-24 | Bristol-Myers Squibb Company | Inhibitori piroltriazin kinaze |
| US7605160B2 (en) * | 2006-08-09 | 2009-10-20 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7531539B2 (en) * | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CA2662337A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| JP2010502730A (ja) * | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ，インコーポレイティド | 癌の治療法 |
| PE20080931A1 (es) * | 2006-11-08 | 2008-07-19 | Schering Corp | Imidazopirazinas como inhibidores de proteina quinasa |
| US8148522B2 (en) * | 2007-01-02 | 2012-04-03 | Bristol-Myers Squibb Company | Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate |
| EP2111405B1 (en) * | 2007-01-08 | 2010-10-27 | Bristol-Myers Squibb Company | Intermediates useful in preparing certain pyrrolotriazine compounds and a process for making the intermediates |
| DE102007012645A1 (de) | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
| EP2125819B1 (en) * | 2007-03-21 | 2014-10-22 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| CN101687874B (zh) | 2007-04-18 | 2013-01-30 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| AU2008262291A1 (en) * | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| RU2461551C2 (ru) * | 2007-10-24 | 2012-09-20 | Астеллас Фарма Инк. | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль |
| US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| CN103169973A (zh) * | 2007-11-12 | 2013-06-26 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌 |
| CA2708157A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| DE102007060172A1 (de) | 2007-12-13 | 2009-06-25 | Bayer Healthcare Ag | Triazolotriazine und Triazolopyrazine und ihre Verwendung |
| DE102008035209A1 (de) | 2008-07-29 | 2010-02-04 | Bayer Schering Pharma Aktiengesellschaft | Triazolotriazine und Triazolopyrazine und ihre Verwendung |
| PE20091074A1 (es) * | 2007-12-13 | 2009-07-26 | Bayer Healthcare Ag | Triazolotriazinas y triazolopirazinas y su uso |
| JP5989965B2 (ja) * | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| CA2710929A1 (en) * | 2008-01-28 | 2009-08-06 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| JP5496915B2 (ja) | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ，インコーポレーテッド | ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法 |
| DE102008023801A1 (de) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine |
| US8476430B2 (en) | 2008-07-24 | 2013-07-02 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| EA021293B1 (ru) * | 2008-12-08 | 2015-05-29 | Джилид Коннектикут, Инк. | ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CN102307474B (zh) | 2008-12-08 | 2015-04-01 | 吉利德康涅狄格股份有限公司 | 咪唑并吡嗪syk抑制剂 |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| JP5487214B2 (ja) | 2008-12-19 | 2014-05-07 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物 |
| ES2539620T3 (es) | 2008-12-19 | 2015-07-02 | Cephalon, Inc. | Pirrolotriazina como inhibidor de ALK y de JAK2 |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| WO2011088045A1 (en) | 2010-01-12 | 2011-07-21 | Ambit Biosciences Corporation | Aurora kinase compounds and methods of their use |
| EP2526102B1 (en) | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibitors of PI3 kinase |
| JP5093527B2 (ja) * | 2010-02-10 | 2012-12-12 | 日本電気株式会社 | 複合光導波路、波長可変フィルタ、波長可変レーザ、および光集積回路 |
| CN103168039B (zh) | 2010-03-11 | 2016-08-03 | 吉利德康涅狄格公司 | 咪唑并吡啶类syk抑制剂 |
| US20130131057A1 (en) | 2010-05-13 | 2013-05-23 | Centro Nacional De Investigaciones Oncologicas (Cnio | New bicyclic compounds as pi3-k and mtor inhibitors |
| US8685969B2 (en) | 2010-06-16 | 2014-04-01 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| KR101548443B1 (ko) | 2011-02-23 | 2015-08-28 | 화이자 인코포레이티드 | 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진 |
| EA026655B1 (ru) | 2011-09-15 | 2017-05-31 | Новартис Аг | 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ |
| US9724352B2 (en) | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2014210087A1 (en) | 2013-06-25 | 2014-12-31 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
| TWI648272B (zh) | 2013-06-25 | 2019-01-21 | 美商必治妥美雅史谷比公司 | 經取代之四氫咔唑及咔唑甲醯胺化合物 |
| EA029281B1 (ru) | 2013-07-30 | 2018-03-30 | Джилид Коннектикут, Инк. | Полиморф ингибиторов syk |
| CA2919522C (en) | 2013-07-30 | 2019-02-26 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
| CN105764516A (zh) | 2013-12-04 | 2016-07-13 | 吉利德科学公司 | 治疗癌症的方法 |
| TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| US9856263B2 (en) | 2014-04-28 | 2018-01-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
| BR112016028641A2 (pt) | 2014-07-14 | 2017-08-22 | Gilead Sciences Inc | ?método para tratar câncer? |
| EA034931B1 (ru) | 2014-10-24 | 2020-04-08 | Бристол-Майерс Сквибб Компани | Индолкарбоксамидные соединения |
| JP6592512B2 (ja) | 2014-10-24 | 2019-10-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 三環式アトロプ異性体の化合物 |
| SI3209651T1 (sl) | 2014-10-24 | 2019-12-31 | Bristol-Myers Squibb Company | Derivati karbazola |
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CN108349979B (zh) | 2015-11-02 | 2021-04-09 | 詹森药业有限公司 | [1,2,4]三唑并[1,5-a]嘧啶-7-基化合物 |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| JP6791979B2 (ja) * | 2016-03-01 | 2020-11-25 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用 |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| CN109890824B (zh) | 2016-11-02 | 2022-05-24 | 詹森药业有限公司 | 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物 |
| EA039102B1 (ru) | 2016-11-02 | 2021-12-03 | Янссен Фармацевтика Нв | Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2 |
| MY193511A (en) | 2016-11-02 | 2022-10-17 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| AU2017382870B2 (en) | 2016-12-22 | 2022-03-24 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| CN110582489B (zh) * | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| CA3073871A1 (en) | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
| BR122023024273A2 (pt) | 2018-02-27 | 2024-02-20 | Incyte Corporation | Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos |
| CR20200520A (es) | 2018-03-30 | 2021-03-09 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2019217821A1 (en) | 2018-05-11 | 2019-11-14 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
| WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
| US20210347758A1 (en) | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
| CN111018860B (zh) * | 2018-10-10 | 2022-06-10 | 中国药科大学 | 吡咯并三嗪类化合物及其应用 |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CN113950479A (zh) | 2019-02-22 | 2022-01-18 | 克洛诺斯生物股份有限公司 | 作为syk抑制剂的缩合吡嗪的固体形式 |
| CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| EP4010342A1 (en) | 2019-08-09 | 2022-06-15 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| WO2021067217A1 (en) | 2019-09-30 | 2021-04-08 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| JP7535600B2 (ja) | 2020-06-01 | 2024-08-16 | ナンジン ルイジエ ファーマ シーオー．，エルティーディー． | 化合物および脾臓チロシンキナーゼ阻害剤としてのその使用 |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| AU2023249795A1 (en) | 2022-04-08 | 2024-10-17 | Shy Therapeutics, Llc | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2026064361A1 (en) * | 2024-09-20 | 2026-03-26 | Fmc Corporation | Linked bicyclic compounds as pesticides |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000071129A1 (en) * | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| WO2003000693A1 (de) * | 2001-06-22 | 2003-01-03 | Bayer Healthcare Ag | Imidazotriazine als phosphodiesterase inhibitoren |
| WO2004005291A1 (de) * | 2002-07-08 | 2004-01-15 | Bayer Healthcare Ag | Heterocyclisch substituierte imidazotriazine |
| WO2004005290A1 (de) * | 2002-07-08 | 2004-01-15 | Bayer Healthcare Ag | Substituierte imidazotriazine |
| US20040063715A1 (en) * | 2002-09-23 | 2004-04-01 | Schering Corporation | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
| WO2004043912A2 (en) * | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| WO2004087056A2 (en) * | 2003-03-28 | 2004-10-14 | Scios Inc. | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ |
| WO2004087707A1 (en) * | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
Family Cites Families (185)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB828847A (en) | 1956-12-14 | 1960-02-24 | Ilford Ltd | Improvements in or relating to cyanine dyes |
| FR1242962A (fr) | 1959-08-25 | 1960-10-07 | Kodak Pathe | Nouveau procédé pour la préparation de colorants sensibilisateurs de la série des cyanines et des mérocyanines et produits obtenus |
| DE2844606A1 (de) | 1978-10-13 | 1980-04-24 | Bayer Ag | Heterocyclische farbstoffe |
| US4260776A (en) | 1978-01-25 | 1981-04-07 | Bayer Aktiengesellschaft | Heterocyclic dyestuffs |
| GB9222253D0 (en) | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
| GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| EP1655369A1 (en) | 1995-12-18 | 2006-05-10 | Sugen, Inc. | Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
| US6716575B2 (en) | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| US7119174B2 (en) | 1995-12-18 | 2006-10-10 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9625184D0 (en) | 1996-12-04 | 1997-01-22 | Celltech Therapeutics Ltd | Chemical compounds |
| US6057329A (en) | 1996-12-23 | 2000-05-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| ATE342971T1 (de) | 1997-08-15 | 2006-11-15 | Univ Hiroshima | Den zellzyklus regulierende proteine |
| WO1999010349A1 (en) | 1997-08-22 | 1999-03-04 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| US6143480A (en) | 1998-09-03 | 2000-11-07 | Fuji Photo Film Co., Ltd. | Leuco dye and image recording medium containing the same |
| US6706491B1 (en) | 1999-04-09 | 2004-03-16 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of genes regulated by p21 |
| US20050113460A1 (en) | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| US6982265B1 (en) * | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| JP2003505064A (ja) | 1999-07-21 | 2003-02-12 | ユニバーシティー オブ マサチューセッツ | キナーゼ遮断ポリペプチド及びその使用 |
| WO2001014378A1 (en) * | 1999-08-23 | 2001-03-01 | Shionogi & Co., Ltd. | PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES |
| KR20020032608A (ko) | 1999-09-21 | 2002-05-03 | 다비드 에 질레스 | 퀴나졸린 화합물 및 이를 함유하는 제약 조성물 |
| GB9922173D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| US7709479B1 (en) | 1999-09-21 | 2010-05-04 | Astrazeneca | Quinazoline derivatives and their use as pharmaceuticals |
| GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| US6455525B1 (en) | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
| OA12514A (en) | 1999-12-24 | 2006-05-29 | Aventis Pharma Ltd | Azaindoles. |
| US6977259B2 (en) | 2000-01-28 | 2005-12-20 | Astrazeneca Ab | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
| HUP0202332A2 (en) | 2000-02-05 | 2002-10-28 | Vertex Pharma | Pyrazole compositions useful as inhibitors of erk |
| CA2369076A1 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
| EP1134221A1 (en) | 2000-03-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines as lkB kinase inhibitors |
| EP1209158A1 (en) | 2000-11-18 | 2002-05-29 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines |
| JP2001294772A (ja) | 2000-04-10 | 2001-10-23 | Fuji Photo Film Co Ltd | 着色組成物、インクジェット用インク及びインクジェット記録方法 |
| JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| ATE394102T1 (de) | 2000-06-28 | 2008-05-15 | Astrazeneca Ab | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren |
| US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| ES2349762T3 (es) | 2000-08-10 | 2011-01-11 | Pfizer Italia S.R.L. | Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden. |
| US6352858B1 (en) | 2000-09-11 | 2002-03-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of BTAK expression |
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2002215053A1 (en) | 2000-11-27 | 2002-06-24 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| US6455559B1 (en) | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| CZ20031315A3 (cs) | 2000-11-28 | 2004-04-14 | Pfizer Products Inc. | Soli isothiazolkarboxamidu a jejich použití jako prostředků proti hyperproliferaci |
| FR2818278B1 (fr) * | 2000-12-20 | 2003-02-28 | Sod Conseils Rech Applic | Inhibiteurs de kinases dependantes des cyclines (cdk) et de la glycogene synthase kinase-3 (gsk-3) |
| EP1345941A1 (fr) * | 2000-12-20 | 2003-09-24 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3) |
| NZ526472A (en) | 2000-12-21 | 2004-04-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
| MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| CA2447405C (en) | 2001-05-14 | 2006-10-17 | Pfizer Products Inc. | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| CA2448076A1 (en) | 2001-05-24 | 2002-11-28 | Masahiko Hayakawa | 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives |
| WO2002096867A2 (en) | 2001-05-30 | 2002-12-05 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| US6762179B2 (en) | 2001-05-31 | 2004-07-13 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
| CA2446756C (en) | 2001-06-01 | 2011-03-08 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| JP2004535493A (ja) | 2001-06-22 | 2004-11-25 | ザ プロクター アンド ギャンブル カンパニー | 親油性流体系用の布地ケア組成物 |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| ATE345341T1 (de) | 2001-07-19 | 2006-12-15 | Pfizer Italia Srl | Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel |
| US20040235867A1 (en) | 2001-07-24 | 2004-11-25 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| AU2002322775A1 (en) | 2001-07-27 | 2003-02-17 | The Regents Of The University Of California | Stk15 (stk6) gene polymorphism and methods of determining cancer risk |
| WO2003011287A1 (en) | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Pyrazolon derivatives as inhibitors of gsk-3 |
| EP1435948A1 (en) | 2001-08-06 | 2004-07-14 | Pharmacia Italia S.p.A. | Aminoisoxazole derivatives active as kinase inhibitors |
| US20030073692A1 (en) | 2001-08-07 | 2003-04-17 | Pharmacia & Upjohn S.P.A. | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| WO2003020276A1 (en) | 2001-08-30 | 2003-03-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| JP2005507892A (ja) | 2001-09-19 | 2005-03-24 | ファルマシア・コーポレーション | 炎症の治療のための置換されたピラゾリルベンゼンスルファミド化合物 |
| ATE363473T1 (de) | 2001-09-19 | 2007-06-15 | Pharmacia Corp | Substituierte pyrazoloverbindungen zur behandlung von entzündungen |
| MXPA04002667A (es) | 2001-09-19 | 2004-06-18 | Pharmacia Corp | Compuestos de pirazolilo sustituido para el tratamiento de la inflacion. |
| BR0212613A (pt) | 2001-09-19 | 2004-08-31 | Pharmacia Corp | Compostos de indazol substituìdos para o tratamento de inflamação |
| WO2003028720A1 (en) | 2001-09-26 | 2003-04-10 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| GB0124299D0 (en) | 2001-10-10 | 2001-11-28 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
| ATE407678T1 (de) | 2001-10-17 | 2008-09-15 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| US20040010027A1 (en) | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
| SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| DE60234125D1 (de) | 2001-12-24 | 2009-12-03 | Astrazeneca Ab | E inhibitoren |
| FR2836914B1 (fr) | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| AU2003218215A1 (en) | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines as inhibitors of protein kinases |
| WO2003078423A1 (en) | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Compositions useful as inhibitors of protein kinases |
| EP1485100B1 (en) | 2002-03-15 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Azinylaminoazoles as inhibitors of protein kinases |
| DE60327999D1 (de) | 2002-03-15 | 2009-07-30 | Vertex Pharma | Azolylaminoazine als inhibitoren von proteinkinasen |
| SE0200979D0 (sv) | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| CA2480880C (en) | 2002-04-08 | 2011-03-22 | Merck & Co., Inc. | Inhibitors of akt activity |
| AU2003244978A1 (en) | 2002-04-15 | 2003-10-27 | Inserm | Methods to identify anti-tumoral agents inhibiting rasgap / aurora kinase interactions |
| AU2003237121A1 (en) | 2002-04-26 | 2003-11-10 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| EP1549318B1 (en) | 2002-05-01 | 2010-02-17 | Vertex Pharmaceuticals Incorporated | Crystal structure of aurora-2 protein and binding pockets thereof |
| JP4751063B2 (ja) | 2002-05-17 | 2011-08-17 | ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ | キナーゼ阻害剤として活性のアミノインダゾール誘導体、それらの調製方法、及びそれらを含む薬学的組成物 |
| WO2003101983A1 (en) | 2002-05-31 | 2003-12-11 | Yamanouchi Pharmaceutical Co., Ltd. | Tetrahydropyran derivative |
| FR2840905B1 (fr) | 2002-06-12 | 2006-07-07 | Centre Nat Rech Scient | Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers |
| AU2002311176A1 (en) | 2002-06-12 | 2003-12-31 | Axia Biosciences, Inc. | Chfr protein-catalyzed polyubiquitination of aurora kinase a and aurora kinase b |
| ES2282647T3 (es) | 2002-06-14 | 2007-10-16 | MERCK & CO., INC. | Inhibidores de cinesina mitotica. |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| CA2491895C (en) | 2002-07-09 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| WO2004006838A2 (en) | 2002-07-15 | 2004-01-22 | Sugen, Inc. | Novel kinases |
| ES2304531T3 (es) | 2002-07-17 | 2008-10-16 | Pfizer Italia S.R.L. | Derivados heterobiciclicos de pirazol como inhibidores de quinasa. |
| CA2493680C (en) | 2002-07-25 | 2010-09-07 | Pharmacia Italia S.P.A. | Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| JP2005537290A (ja) | 2002-07-25 | 2005-12-08 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物 |
| CA2493625A1 (en) | 2002-07-25 | 2004-02-19 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| MXPA05001804A (es) | 2002-08-14 | 2005-05-27 | Vertex Pharma | Inhibidores de proteinas cinasas y usos de los mismos. |
| US20040157804A1 (en) | 2002-10-16 | 2004-08-12 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
| AU2003286711A1 (en) | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| US6909001B2 (en) | 2002-12-12 | 2005-06-21 | Pharmacia Corporation | Method of making tricyclic aminocyanopyridine compounds |
| UA81790C2 (uk) | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| AU2003292435A1 (en) | 2002-12-23 | 2004-07-14 | Astrazeneca Ab | 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents |
| JP2006512387A (ja) | 2002-12-24 | 2006-04-13 | アストラゼネカ アクチボラグ | 化合物 |
| ES2290529T3 (es) | 2002-12-24 | 2008-02-16 | Astrazeneca Ab | Derivados de fosfonooxiquinazolina y su uso farmaceutico. |
| MXPA05006920A (es) | 2002-12-24 | 2006-02-10 | Astrazeneca Ab | Compuestos de quinazolina. |
| CL2004000016A1 (es) | 2003-01-21 | 2005-04-15 | Wyeth Corp | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. |
| ATE440087T1 (de) | 2003-01-30 | 2009-09-15 | Boehringer Ingelheim Pharma | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen |
| WO2004070062A2 (en) | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
| CA2513716A1 (en) | 2003-02-14 | 2004-08-26 | Applied Research Systems Ars Holding N.V. | Piperazine-2-carboxamide derivatives |
| BRPI0407544A (pt) | 2003-02-17 | 2006-02-14 | Pharmacia Italia Spa | derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| BR0318145A (pt) | 2003-02-26 | 2006-02-21 | Boehringer Ingelheim Pharma | dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento |
| MXPA05009719A (es) | 2003-03-11 | 2005-10-18 | Pharmacia Italia Spa | Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. |
| WO2004083203A1 (en) | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| WO2004090106A2 (en) | 2003-04-04 | 2004-10-21 | Vertex Pharmaceuticals Incorporated | Crystal structures of human pim-1 kinase protein complexes and binding pockets thereof, and uses thereof in drug design |
| CN1809557B (zh) | 2003-04-16 | 2012-07-04 | 阿斯利康(瑞典)有限公司 | 化合物 |
| CN1809536A (zh) | 2003-04-24 | 2006-07-26 | 麦克公司 | Akt活性抑制剂 |
| AU2004233828B2 (en) | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| ATE461179T1 (de) | 2003-04-24 | 2010-04-15 | Merck Sharp & Dohme | Hemmer der akt aktivität |
| EP1620095A4 (en) | 2003-04-24 | 2009-04-01 | Merck & Co Inc | HEMMER OF ACT ACTIVITY |
| US20040242559A1 (en) | 2003-04-25 | 2004-12-02 | Aventis Pharma S.A. | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors |
| AU2004255153B2 (en) | 2003-05-01 | 2007-11-22 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| DK1618092T3 (da) | 2003-05-01 | 2011-01-31 | Bristol Myers Squibb Co | Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere |
| WO2005000200A2 (en) | 2003-05-09 | 2005-01-06 | Sugen, Inc. | Novel kinases |
| PT1636236E (pt) | 2003-05-22 | 2013-12-16 | Nerviano Medical Sciences Srl | Derivados de pirazol-quinazolina, processo para sua preparação e sua utilização como inibidores de cinase |
| US7345046B2 (en) | 2003-05-30 | 2008-03-18 | Chiron Corporation | Heteroaryl-fused pyrimidinyl compounds as anticancer agents |
| ATE401080T1 (de) | 2003-06-02 | 2008-08-15 | Astrazeneca Ab | (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs |
| TW200505452A (en) | 2003-06-17 | 2005-02-16 | Astrazeneca Ab | Chemical compounds |
| WO2004113335A2 (en) | 2003-06-20 | 2004-12-29 | Chiron Corporation | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
| WO2005009348A2 (en) | 2003-06-25 | 2005-02-03 | Ariad Pharmaceuticals, Inc. | Substituted purine derivatives |
| US20060178318A1 (en) | 2003-07-03 | 2006-08-10 | Shubha Anand | Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| SI1641775T1 (sl) | 2003-07-03 | 2009-08-31 | Euro Celtique Sa | 2-piridin alkinski derivati, uporabni za zdravljenje bolečine |
| GB0315657D0 (en) | 2003-07-03 | 2003-08-13 | Astex Technology Ltd | Pharmaceutical compounds |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| GB0315966D0 (en) | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
| US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP1648900A4 (en) | 2003-07-11 | 2010-02-10 | Ariad Pharma Inc | PHOSPHORUS MACROCYCLES |
| EP1781659B1 (en) | 2003-07-16 | 2008-11-05 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| MXPA06000540A (es) | 2003-07-16 | 2006-03-30 | Janssen Pharmaceutica Nv | Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa cinasa 3. |
| EP1654247B1 (en) | 2003-07-21 | 2010-01-20 | Merck Serono SA | Alkynyl aryl carboxamides |
| AU2004259357B2 (en) | 2003-07-24 | 2010-02-18 | Euro-Celtique S.A. | Piperidine compounds and pharmaceutical compositions containing them |
| US7619059B2 (en) | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
| US20050026984A1 (en) | 2003-07-29 | 2005-02-03 | Aventis Pharma S.A. | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products |
| JP2007500178A (ja) | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 |
| EP1648875A1 (en) | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| US7094791B2 (en) | 2003-07-31 | 2006-08-22 | Avalon Pharmaceuticals, Inc. | Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof |
| US7279575B2 (en) | 2003-08-08 | 2007-10-09 | Pfizer Italia S.R.L. | Pyrimidylpyrrole derivatives active as kinase inhibitors |
| US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| AU2004267094A1 (en) | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors |
| AR045595A1 (es) | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
| AU2004272306A1 (en) | 2003-09-12 | 2005-03-24 | Merck Serono Sa | Benzimidazole acetonitriles |
| AU2004272345A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| AU2004272346A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| ES2305844T3 (es) | 2003-09-16 | 2008-11-01 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de tirosina cinasa. |
| AU2003270848A1 (en) | 2003-09-17 | 2005-04-27 | Sunesis Pharmaceuticals, Inc. | Identification of kinase inhibitors |
| EP1667684A1 (en) | 2003-09-17 | 2006-06-14 | ICOS Corporation | Use of chk1 inhibitors to control cell proliferation |
| US20070185007A1 (en) | 2003-09-19 | 2007-08-09 | Haolun Jin | Aza-quinolinol phosphonate integrase inhibitor compounds |
| US20050085531A1 (en) | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| AU2004282179B2 (en) | 2003-10-14 | 2011-05-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein kinase inhibitors |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| WO2005035527A1 (en) | 2003-10-14 | 2005-04-21 | Pharmacia Corporation | Substituted pyrazinone compounds for the treatment of inflammation |
| WO2005040159A1 (en) | 2003-10-17 | 2005-05-06 | Astrazeneca Ab | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
| WO2005037797A1 (en) | 2003-10-21 | 2005-04-28 | Pharmacia Corporation | Substituted pyrazole urea compounds for the treatment of inflammation |
| CA2542880A1 (en) | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
| BRPI0415678A (pt) | 2003-10-23 | 2006-12-19 | Pharmacia Corp | compostos de pirimidina para o tratamento de inflamação |
| WO2005044270A1 (en) | 2003-11-04 | 2005-05-19 | 4Sc Ag | Oxadiazolopyrazine derivatives as pharmaceutically active compounds |
| US8969372B2 (en) | 2003-11-14 | 2015-03-03 | Aptose Boisciences Inc. | Aryl imidazoles and their use as anti-cancer agents |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| WO2005051308A2 (en) | 2003-11-19 | 2005-06-09 | Signal Pharmaceuticals, Llc | Methods of treating diseases and disorders by targeting multiple kinases |
| FR2864084B1 (fr) | 2003-12-17 | 2006-02-10 | Aventis Pharma Sa | Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments |
| WO2005123672A2 (en) | 2004-06-14 | 2005-12-29 | Takeda San Diego, Inc. | Kinase inhibitors |
| FR2876377B1 (fr) | 2004-10-11 | 2007-03-16 | Univ Claude Bernard Lyon | Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes |
| ATE479687T1 (de) * | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| EP1896472A1 (de) | 2005-06-09 | 2008-03-12 | Boehringer Ingelheim International GmbH | Alpha-carboline als cdk-1 inhibitoren |
| US7442700B2 (en) * | 2005-07-01 | 2008-10-28 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
-
2005
- 2005-10-14 AT AT05810353T patent/ATE479687T1/de not_active IP Right Cessation
- 2005-10-14 EP EP05810353.2A patent/EP1812439B2/en not_active Expired - Lifetime
- 2005-10-14 DE DE602005023333T patent/DE602005023333D1/de not_active Expired - Lifetime
- 2005-10-14 JP JP2007536949A patent/JP2008516973A/ja not_active Withdrawn
- 2005-10-14 WO PCT/US2005/037059 patent/WO2006044687A2/en not_active Ceased
- 2005-10-14 US US11/251,616 patent/US7713973B2/en active Active
-
2010
- 2010-04-06 US US12/755,301 patent/US8288536B2/en not_active Expired - Fee Related
-
2011
- 2011-12-26 JP JP2011284364A patent/JP5524171B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-17 JP JP2013006060A patent/JP2013121966A/ja not_active Ceased
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000071129A1 (en) * | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| WO2003000693A1 (de) * | 2001-06-22 | 2003-01-03 | Bayer Healthcare Ag | Imidazotriazine als phosphodiesterase inhibitoren |
| WO2004005291A1 (de) * | 2002-07-08 | 2004-01-15 | Bayer Healthcare Ag | Heterocyclisch substituierte imidazotriazine |
| WO2004005290A1 (de) * | 2002-07-08 | 2004-01-15 | Bayer Healthcare Ag | Substituierte imidazotriazine |
| US20040063715A1 (en) * | 2002-09-23 | 2004-04-01 | Schering Corporation | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
| WO2004043912A2 (en) * | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| WO2004087056A2 (en) * | 2003-03-28 | 2004-10-14 | Scios Inc. | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ |
| WO2004087707A1 (en) * | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008545660A (ja) * | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| JP2009179644A (ja) * | 2005-05-20 | 2009-08-13 | Vertex Pharmaceut Inc | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| JP2012505234A (ja) * | 2008-10-08 | 2012-03-01 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
| JP2012517965A (ja) * | 2009-02-13 | 2012-08-09 | バイエル ファーマ アクチエンゲゼルシャフト | Ａｋｔインヒビターとしての融合されたピリミジン |
| JP2013523884A (ja) * | 2010-04-14 | 2013-06-17 | アレイ バイオファーマ、インコーポレイテッド | ＪＡＫキナーゼの阻害剤としての５，７置換イミダゾ［１，２−ｃ］ピリミジン |
| JP2015205905A (ja) * | 2010-04-14 | 2015-11-19 | アレイ バイオファーマ、インコーポレイテッド | ＪＡＫキナーゼの阻害剤としての５，７置換イミダゾ［１，２−ｃ］ピリミジン |
| JP2015518010A (ja) * | 2012-05-31 | 2015-06-25 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ | ピロロ［２，１−ｆ］［１，２，４］トリアジン系化合物、その製造方法および用途 |
| JP2017511365A (ja) * | 2014-04-17 | 2017-04-20 | アッヴィ・インコーポレイテッド | 複素環キナーゼ阻害薬 |
| US10280184B2 (en) | 2014-04-17 | 2019-05-07 | Abbvie Inc. | Heterocyclic kinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005023333D1 (de) | 2010-10-14 |
| US8288536B2 (en) | 2012-10-16 |
| US7713973B2 (en) | 2010-05-11 |
| US20100216765A1 (en) | 2010-08-26 |
| JP2012102121A (ja) | 2012-05-31 |
| ATE479687T1 (de) | 2010-09-15 |
| JP2013121966A (ja) | 2013-06-20 |
| WO2006044687A2 (en) | 2006-04-27 |
| EP1812439B1 (en) | 2010-09-01 |
| US20060084650A1 (en) | 2006-04-20 |
| EP1812439A2 (en) | 2007-08-01 |
| WO2006044687A3 (en) | 2006-07-20 |
| JP5524171B2 (ja) | 2014-06-18 |
| EP1812439B2 (en) | 2017-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5524171B2 (ja) | キナーゼ阻害剤 | |
| JP5150878B2 (ja) | キナーゼ阻害剤 | |
| US9371328B2 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| JP2007514759A (ja) | キナーゼ阻害剤 | |
| JP2008502687A (ja) | キナーゼ阻害剤 | |
| JP2009532375A (ja) | キナーゼ阻害剤 | |
| US20090291938A1 (en) | Polo-like kinase inhibitors | |
| HUE035919T2 (en) | Macrocyclic pyridazinone derivatives | |
| EP1463730A1 (en) | Pyrazoloparidazine derivatives | |
| JP2010505961A (ja) | キナーゼ阻害剤 | |
| EP2145877B1 (en) | Aurora Kinase inhibitors | |
| US12583836B2 (en) | Sulphonamide compounds | |
| JP2007533753A (ja) | インドール誘導体及びキナーゼ阻害剤としてのその使用 | |
| CA2723745A1 (en) | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | |
| US10696690B2 (en) | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | |
| JP2025501765A (ja) | 二官能性スルホンアミド化合物 | |
| US7550598B2 (en) | Kinase inhibitors | |
| JP2010505962A (ja) | キナーゼ阻害剤 | |
| TW202019909A (zh) | 新穎胺基-嘧啶酮基衍生物、其製備之方法及包含其之醫藥組合物 | |
| HK1138842B (en) | Kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081014 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081014 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111025 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111226 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120514 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120705 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120824 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20130118 |